|
Training Advisory Committee (TAC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ
|
OD/OER, CSR, FIC, NCATS, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM, OD/DPCPSI/ORIP
|
The Training Advisory Committee (TAC) advises on programmatic, review, and management issues related to extramural research training, research education, career development and diversity programs and the Loan Repayment Programs (LRP), and evaluation of these programs. TAC provides a trans-NIH forum to identify and discuss issues related to these programs and recommend solutions.
|
|
Trans-Agency (Medical) Imaging Phantom (TAIP) Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NIBIB
|
A common set of scientifically validated medical phantoms that have long term curation, convenient dissemination, associated measurement protocols and analysis software, will be of great benefit to the FDA, NIH, NIST and to the scientific community they serve. This working group is created to enhance collaboration between FDA, NIST, and NIH to cooperate, where possible, on the development, validation, and dissemination of these medical calibration objects and to maintain at library of these medical phantoms for use by the larger medical community.
|
|
Trans-Agency Meeting on Adult Obesity Treatment and Prevention: State of the Science, Research Gaps, and Opportunities for Future Research
|
Meeting/ Workshop
|
AHRQ, CDC, HRSA, OASH
|
NHLBI, NCI, NIDDK, NIAMS, NCCIH, NIMHD, OD/DPCPSI/OBSSR, OD/DPCPSI/OPA
|
The Trans-Agency Meeting on Adult Obesity Treatment and Prevention: State of the Science, Research Gaps and Opportunities for Future Research was held virtually on September 16 and 24, 2021. The purpose of this meeting was to bring together key staff from NIH and other federal and non-governmental organizations to discuss the current state of adult obesity prevention and treatment research, knowledge gaps, and opportunities for future research and directions. The meeting was attended by 58 participants across 20 NIH Institutes, Centers or Offices (ICOs), five (5) other federal agencies, and two (2) non-governmental organizations (NGOs). The meeting laid the groundwork for a future workshop on this topic and other trans-agency activities in FY 2022 and beyond. The federal agencies represented at this meeting included NIH, HHS Health Resources and Services Administration (HRSA), HHS Office of the Assistant Secretary for Health (OASH), Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control (CDC), and the Veterans Health Administration (VA).
|
|
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, ASPR
|
NIAID
|
The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of US and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration in order to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation.
|
|
Trans-HHS program for Multi-System Inflammatory Syndrome in Children (MIS-C) and pediatric SARS-CoV-2 (CARING)
|
Research Initiative
|
CDC, FDA, OASH
|
NHLBI
|
Staff from NHLBI and NICHD, the NIH co-leads, as well as NIAID collaborate with the Office of the Assistant Secretary of Health, CDC, and the FDA to guide a federal research program for MIS-C and pediatric SARS-CoV-2.
|
|
Trans-NIH Liver Cancer Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NCI, NIDDK, NIAAA, NIAID
|
The charge of this working group is to develop an integrated NIH-wide plan for research in liver cancer that addresses basic, behavioral, translational, and clinical aspects of liver cancer aimed at understanding the basic mechanisms, the prevention, and cure of the disease. Additionally, the working group is interested in global health and health disparities research on liver disease.
|
|
Trans-NIH Mitochondrial Disorders Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NINDS, NIMH, NIA, NIGMS, NICHD, NIEHS, NEI, NIDDK, NCATS, NCI, NHLBI, NIAMS
|
The Trans-NIH Mitochondrial Disorders Working Group meets every 2-3 years to discuss and share information about ongoing funded research related to mitochondrial disorders including mechanisms and therapies.
|
|
Trans-NIH Working Group for Objective Measures in Cancer
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NIBIB, NIDDK
|
An National Institutes of Health (NIH) working group was formed to develop and consolidate wearable, passive and continuous out-of-clinic monitoring strategies for clinical assessment and understanding of disease progression in cancer. The goal of this group and its activities is to examine how these devices and techniques can be used to assess and understand cancer progression from multi-parameter data (context, vitals, and/or chemistry). Currently, several non-HHS agencies (National Institute of Standards and Technology (NIST), Department of Defense (DoD), Department of Energy (DOE), the National Aeronautics and Space Administration (NASA) and HHS agencies (NIH and the Food and Drug Administration) are also involved in these discussions and will integrate their expertise/mission to propagate for medical purposes.
|
|
Translational Science Interagency Fellowship (TSIF)
|
Training Initiative
|
FDA
|
NCATS
|
The Translational Science Interagency Fellowship (TSIF) program is a three-year postdoctoral fellowship opportunity jointly sponsored by the National Center for Advancing Translational Science (NCATS) and the U.S. Food and Drug Administration (FDA). The program aims to provide training in both translational science and regulatory science. The common goal of NCATS and the FDA is to bring safe and effective drugs, regimens, and devices from bench-to-bedside as quickly and efficiently as possible. To that end, fellows are trained in preclinical translational science, technology development, and regulatory research and review. By combining training in translational science and research-related regulatory review, the program enables fellows to build awareness of regulatory requirements into the early stages of medical product development thereby improving efficiencies in both the development and review processes. Fellows in this program will develop valuable skills for future careers in academia, the pharmaceutical industry, and government.
|
|
Transplant Cancer Match Study
|
Research Initiative
|
HRSA
|
NCI
|
A study linking databases of US transplant recipients, donors, and waitlist candidates to multiple US cancer registries to evaluate the spectrum of cancer risk and outcomes in the transplant population.
|